Key Inclusion Criteria:

          -  Documented diagnosis of B-cell CLL, according to International Workshop on Chronic
             Lymphocytic Leukemia 2008

          -  Presence of 17p deletion in CLL cells as demonstrated by fluorescence in-situ
             hybridization (FISH) testing

          -  No prior therapy for CLL other than corticosteroids for disease complications

          -  CLL that warrants treatment

          -  Presence of measurable lymphadenopathy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

        Key Exclusion Criteria:

          -  Known histological transformation from CLL to an aggressive lymphoma (ie, Richter
             transformation)

          -  Known presence of myelodysplastic syndrome

          -  History of a non-CLL malignancy except for the following:

               -  the malignancy has been in remission without treatment for ≥ 5 years prior to
                  enrollment, or

               -  carcinoma in situ of the cervix, or

               -  adequately treated basal or squamous cell skin cancer or other localized
                  non-melanoma skin cancer, or

               -  asymptomatic prostate cancer without known metastatic disease and with no current
                  requirement for therapy or requiring only hormonal therapy and with normal
                  prostate specific antigen for ≥ 1 year prior to enrollment, or

               -  ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone, or

               -  other adequately treated Stage 1 or 2 cancer currently in complete remission

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
             enrollment

          -  Ongoing liver injury

          -  History of noninfectious pneumonitis

          -  Ongoing inflammatory bowel disease

          -  History of prior allogeneic bone marrow progenitor cell or solid organ transplantation

          -  Ongoing immunosuppressive therapy other than corticosteroids

          -  Received last dose of study drug on another therapeutic clinical trial within 30 days
             prior to enrollment

          -  Prior or ongoing clinically significant illness, medical condition, surgical history,
             physical finding, electrocardiogram (ECG) finding, or laboratory abnormality

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.